0.00Open1.00Pre Close0 Volume1 Open Interest2.50Strike Price0.00Turnover1080.51%IV0.14%PremiumJan 17, 2025Expiry Date1.00Intrinsic Value100Multiplier11DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.8688Delta0.0324Gamma1.41Leverage Ratio-0.0657Theta0.0002Rho1.23Eff Leverage0.0013Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet